BioAge’s BGE-102 Achieves Over 85% Reduction in hsCRP, Setting New Benchmark in Inflammation Trials
New Data Shows BGE-102 Delivers Profound and Consistent Biomarker Reduction
BioAge Labs (NASDAQ:BIOA) has unveiled comprehensive Phase 1 results for BGE-102, its novel, orally available NLRP3 inhibitor, designed to tackle chronic inflammation linked with cardiovascular risk and metabolic diseases. Both 60 mg (21 days, n=15) and 120 mg (14 days, n=14) once-daily regimens resulted in median reductions of =85% in high-sensitivity C-reactive protein (hsCRP) among participants with obesity and elevated inflammation, positioning BGE-102 at the forefront of clinical inflammation control.
hsCRP Reductions Set a High Bar for NLRP3 Inhibitor Efficacy
BGE-102 delivered rapid, robust, and durable reductions in hsCRP—a key inflammatory biomarker and a strong predictor of cardiovascular risk. A closer look at key results:
| Dose | Duration | Median hsCRP Reduction (Day 7) | Median hsCRP Reduction (Day 14) | Median hsCRP Reduction (End of Dosing) | % Participants Normalized hsCRP (<2 mg/L) | % Participants hsCRP =1 mg/L |
|---|---|---|---|---|---|---|
| 60 mg | 21 days | 85% | 80% | 86% | 87% (13/15) | 60% (9/15) |
| 120 mg | 14 days | 83% | 86% | 86% | 93% (13/14) | 71% (10/14) |
Notably, the majority of treated subjects reached normal hsCRP levels, and a significant fraction achieved <1 mg/L, underscoring both regimens’ potency. These results are particularly relevant given historical cardiovascular outcome studies, where dropping hsCRP below 2 mg/L has correlated with a 25% reduction in major adverse events.
Reductions Seen Across IL-6 and Fibrinogen Add to BGE-102’s Appeal
| Biomarker | 60 mg Median Reduction | 120 mg Median Reduction |
|---|---|---|
| IL-6 (Day 7 / Day 14 / Day 21) | 78% / 70% / 55% | 69% / 58% / — |
| Fibrinogen (Day 7 / Day 14 / Day 21) | 20% / 19% / 23% | 24% / 30% / — |
These findings confirm BGE-102’s upstream immune-modulating effects, potentially extending beyond simple hsCRP lowering to comprehensive anti-inflammatory impact. Consistent reductions across IL-6 and fibrinogen further support its promise in broader inflammation-driven diseases.
Safety Profile Is Favorable Across All Dose Levels
BGE-102 exhibited a clean safety record: all observed adverse events were mild or moderate and self-limiting, with no severe drug-related side effects, no dose dependency, and no withdrawals due to side effects reported. This tolerability profile is an essential foundation for upcoming broader efficacy trials in cardiovascular and ophthalmic indications.
Upcoming Trials to Target Cardiovascular and Ocular Indications
BioAge is moving swiftly into Phase 2, planning a dose-ranging trial for cardiovascular risk in the first half of 2026, targeting hsCRP normalization. A separate Phase 1b/2a study in diabetic macular edema is slated for mid-2026, both leveraging BGE-102’s oral convenience and biomarker potency. If successful, pivotal Phase 3 studies could begin as early as 2027.
Takeaway: A Potential New Model for Inflammation Management
The robust, dose-proven and rapid reductions in key cardiovascular risk biomarkers place BGE-102 in a highly competitive position as a convenient, best-in-class option for anti-inflammatory treatment. The consistency of the efficacy and safety signals could have wide-ranging implications for patients with chronic inflammation, particularly in cardiovascular and retinal disease. Investors and medical professionals may wish to track BioAge’s trial progress closely as the next set of clinical data could redefine standards for NLRP3 inhibition therapies.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI